Corcept Therapeutics (NASDAQ: CORT) reported Q3 EPS of $0.30, $0.10 better than the analyst estimate of $0.20. Revenue for the quarter came in at $96.1 million versus the consensus estimate of $97.19 million.

GUIDANCE:

Corcept Therapeutics sees FY2021 revenue of $365-375 million, versus the consensus of $371 million.

For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.